

Form PTO-1449 (modified)		Temp. Atty. Docket No. 4001.003000	Serial No. 10/621,269
List of Patents and Publications for Applicant's  INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Thorpe <i>et al.</i>	
		Filing Date: July 15, 2003	Group: 1642
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Pages 2, 3, 4</i>	

## U.S. Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Name	Class	Sub Class	Filing Date of App.
	A1	2002/0025319	Feb. 28, 2002	Brams	424	178.1	
	A2	2003/0004097	Jan. 02, 2003	Schroit	514	7	
	A3	2003/0228625	Dec. 11, 2003	Toh <i>et al.</i>	435	7.1	
	A4	2004/0175378	Sep. 09, 2004	Thorpe <i>et al.</i>	424	141.1	
	A5	2004/0208868	Oct. 21, 2004	Thorpe <i>et al.</i>	424	144.1	
	A6	2005/0002941	Jan. 06, 2005	Thorpe <i>et al.</i>	424	178.1	
	A7	2005/0031620	Feb. 10, 2005	Thorpe <i>et al.</i>	424	155.1	
	A8	2005/0129696	Jun. 16, 2005	Thorpe <i>et al.</i>	424	155.1	
	A9	2005/0136059	Jun. 23, 2005	Thorpe <i>et al.</i>	424	155.1	
	A10	5,660,827	Aug. 26, 1997	Thorpe <i>et al.</i>	424	152.1	
	A11	5,677,171	Oct. 14, 1997	Hudziak <i>et al.</i>	435	7.23	
	A12	5,863,538	Jan. 26, 1999	Thorpe <i>et al.</i>	424	136.1	
	A13	6,300,308	Oct. 09, 2001	Schroit	514	8	
	A14	6,312,694	Nov. 06, 2001	Thorpe <i>et al.</i>	424	178.1	
	A15	6,333,348	Dec. 25, 2001	Vogel <i>et al.</i>	514	449	
	A16	6,406,693	Jun. 18, 2002	Thorpe <i>et al.</i>	424	130.1	
	A17	6,783,760	Aug. 31, 2004	Thorpe <i>et al.</i>	424	178.1	
	A18	6,806,354	Oct. 19, 2004	Schroit	530	387.1	
	A19	6,818,213	Nov. 16, 2004	Thorpe <i>et al.</i>	424	130.1	
	A20	7,067,109	Jun. 27, 2006	Thorpe <i>et al.</i>	424	1.49	

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Temp. Atty. Docket No. 4001.003000	Serial No. 10/621,269
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Thorpe <i>et al.</i>	
		Filing Date: July 15, 2003	Group: 1642
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Pages 2, 3, 4</i>	

## Foreign Patent Documents

Exam. Init.	Ref. Des.	Document Number	Date	Country	Class	Sub Class	Translation Yes/No
	B1	WO 00/02584	Jan. 20, 2000	PCT			
	B2	WO 00/02587	Jan. 20, 2000	PCT			
	B3	WO 01/03735	Jan. 18, 2001	PCT			
	B4	WO 01/68709	Sep. 20, 2001	PCT			

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C1	Balasubramanian and Schroit, "Aminophospholipid Asymmetry: A Matter of Life and Death", <i>Annu. Rev. Physiol.</i> , 65:701-734, 2003.
	C2	Beck <i>et al.</i> , "Combination of a Monoclonal Anti-Phosphatidylserine Antibody with Gemcitabine Strongly Inhibits the Growth and Metastasis of Orthotopic Pancreatic Tumors in Mice," <i>Int. J. Cancer</i> , 118:2639-2643, 2006.
	C3	Bowie <i>et al.</i> , "Deciphering the Message in Protein Sequences: Tolerance to Amnio Acid Substitutions", <i>Science</i> , 147:1306-1310, 1990.
	C4	Goren <i>et al.</i> , "Targeting of Stealth Liposomes in erbB-2 (HER/2) Receptor: In Vitro and In Vivo Studies", <i>Brit. J. Cancer</i> , 74:1749-1756, 1996.
	C5	Güssow and Seemann, "Humanization of Monoclonal Antibodies", <i>Methods in Enzymology</i> , 203:99-121, 1991.
	C6	Herbert <i>et al.</i> , Eds., <i>Dictionary of Immunology</i> , 4th ed. London:Academic Press, 1995.
	C7	Huang <i>et al.</i> , "A Monoclonal Antibody that Binds Anionic Phospholipids on Tumor Blood Vessels Enhances the Antitumor Effect of Docetaxel on Human Breast Tumors in Mice", <i>Cancer Res.</i> , 65(10):4408-4416, 2005.
	C8	Ishida <i>et al.</i> , A Combinatorial Approach to Producing Sterically Stabilized (Stealth) Immunoliposomal Drugs", <i>FEBS Letters</i> , 460:129-133, 1999.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

Form PTO-1449 (modified)		Temp. Atty. Docket No. 4001.003000	Serial No. 10/621,269
List of Patents and Publications for Applicant's INFORMATION DISCLOSURE STATEMENT  (Use several sheets if necessary)		Applicant Thorpe <i>et al.</i>	
		Filing Date: July 15, 2003	Group: 1642
U.S. Patent Documents <i>See Page 1</i>	Foreign Patent Documents <i>See Page 2</i>	Other Art <i>See Pages 2, 3, 4</i>	

## Other Art (Including Author, Title, Date Pertinent Pages, Etc.)

Exam. Init.	Ref. Des.	Citation
	C9	Janeway <i>et al.</i> , "The Interaction of the Antibody Molecule with Specific Antigen", <i>Immunobiology</i> , 5th ed., 7 pages, 2001.
	C10	Lewis <i>et al.</i> , "Differential Responses of Human Tumor Cell Lines to Anti-p185HER2 Monoclonal Antibodies", <i>Cancer Immunol. Immunother.</i> , 37:255-263, 1993.
	C11	Luster <i>et al.</i> , "Plasma Protein Beta-2-glycoprotein 1 Mediates Interaction between the Anti-tumor Monoclonal Antibody 3G4 and Anionic Phospholipids on Endothelial Cells, <i>JBC Papers in Press</i> , www.jbc.org/cgi/doi/10.1074/jbc., M605252200:1-20, 2006.
	C12	Maruyama <i>et al.</i> , "Lipid Composition is Important for Highly Efficient Target Binding and Retention of Immunoliposomes", <i>Proc. Natl. Acad. Sci. USA</i> , 87:5744-5748, 1990.
	C13	Ran and Thorpe, "Phosphatidylserine is a Marker of Tumor Vasculature and a Potential Target for Cancer Imaging and Therapy", <i>Int. J. Radiation Oncology Biol. Phys.</i> , 54(5):1479-1484, 2002.
	C14	Ran <i>et al.</i> , "Increased Exposure of Anionic Phospholipids on the Surface of the Tumor Blood Vessels", <i>Cancer Res.</i> , 62:6132-6140, 2002.
	C15	Ran <i>et al.</i> , "Antitumor Effects of a Monoclonal Antibody that Binds Anionic Phospholipids on the Surface of Tumor Blood Vessels in Mice", <i>Clin. Cancer Res.</i> , 11:1551-1562, 2005.
	C16	Rudikoff, "Single Amino Acid Substitution Altering Antigen-Binding Specificity", <i>Proc. Natl. Acad. Sci. USA</i> , 79:1979-1983, 1982.
	C17	Schneider-Gadicke and Riethmüller, "Prevention of Manifest Metastasis with Monoclonal Antibodies: A Novel Approach to Immunotherapy of Solid Tumours", <i>Eur. J. Cancer</i> , 31A(7/8):1326-1330, 1995.
	C18	Stancovski <i>et al.</i> , "Mechanistic Aspects of the Opposing Effects of Monoclonal Antibodies to the ERBB2 Receptor on Tumor Growth", <i>Proc. Natl. Acad. Sci. USA</i> , 88:8691-8695, 1991.
	C19	Strobel and Cannistra, "β1-Integrins Partly Mediate Binding of Ovarian Cancer Cells to Peritoneal Mesothelium in Vitro", <i>Gynecologic Oncology</i> , 73:362-367, 1999.
	C20	Thorpe <i>et al.</i> , "Tumor Infarction: Immunoconjugates that Coagulate the Vasculature of Solid Tumors", <i>Proceeding of the American Association for Cancer Research</i> , 36:488, Abstract #2910, March 1995.

EXAMINER:

DATE CONSIDERED:

EXAMINER: INITIAL IF REFERENCE CONSIDERED, WHETHER OR NOT CITATION IS IN CONFORMANCE WITH MPEP609; DRAW LINE THROUGH CITATION IF NOT IN CONFORMANCE AND NOT CONSIDERED. INCLUDE COPY OF THIS FORM WITH NEXT COMMUNICATION TO APPLICANT.

[illegible]

**DATE CONSIDERED:**

Information Disclosure Statement — PTO-1449 (Modified)